Progesterone-Only Transdermal Patch Availability
No, there is currently no progesterone-only transdermal patch available for clinical use. 1, 2
Current Transdermal Progesterone Status
Progesterone is available only as oral capsules (micronized progesterone 100 mg or 200 mg) and vaginal formulations, but not as a standalone transdermal patch. 1
Transdermal progesterone preparations lack sufficient evidence to substantiate their clinical use, particularly for endometrial protection during estrogen therapy—even with low-dose estradiol, reliable progestogenic effects have not been proven. 2
Poor dermal absorption is the primary barrier: progesterone requires high doses (approximately 25 mg per 24 hours to match physiologic corpus luteum production), making transdermal delivery impractical compared to oral or vaginal routes. 3
Available Combined Estrogen-Progestin Patches
While progesterone-only patches don't exist, combined estradiol-progestin patches are available in select countries:
Sequential regimen: Patches delivering 50 µg estradiol daily for 2 weeks, followed by patches releasing 50 µg estradiol plus 10 µg levonorgestrel daily for 2 weeks. 4
Continuous regimen: Patches delivering 50 µg estradiol plus 7 µg levonorgestrel daily without interruption. 4
These combined patches use levonorgestrel (a synthetic progestin), not natural progesterone, which has different pharmacologic properties and absorption characteristics. 4, 5
Clinical Implications and Alternatives
For endometrial protection during transdermal estrogen therapy, the recommended approach is:
First choice: Transdermal estradiol (50 µg daily) administered continuously with oral micronized progesterone (200 mg daily) or medroxyprogesterone acetate (10 mg daily) for 12–14 days every 28 days. 4
Alternative: Vaginal micronized progesterone (200 mg daily) for 12–14 days every 28 days when combined with continuous transdermal estradiol. 4
Micronized progesterone is preferred over synthetic progestins due to lower cardiovascular and venous thromboembolism risk. 4
Important Caveats
Over-the-counter progesterone creams should not be used for hormone replacement therapy or endometrial protection—their efficacy remains unsubstantiated, with inconsistent pharmacokinetic data and no proven clinical benefit. 6
Transdermal progesterone application alone is not known to pose health risks, but it provides no therapeutic benefit for standard indications. 2
Research into enhancing transdermal progesterone delivery using penetration enhancers remains experimental and has not translated to approved clinical products. 7